PHARMAGREEN BIOTECH INC.: 10-Q filed 2022-08-17
What PHARMAGREEN BIOTECH INC. reported in its quarterly report filed 2022-08-17 (fiscal Q3 2022): 28 published measures, 88 facts as tagged in accession 0001477932-22-006233.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2022-08-17
- Fiscal period
- fiscal Q3 2022
- Accession
- 0001477932-22-006233 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All PHARMAGREEN BIOTECH INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 191,170 | USD | |
| At 2021-09-30 | 373,081 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 2,128,908 | USD | |
| At 2021-09-30 | 2,065,781 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -1,891,080 | USD | |
| At 2021-09-30 | -1,646,042 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 24,262 | USD | |
| At 2021-09-30 | 25,300 | USD | |
| At 2021-06-30 | 19,218 | USD | |
| At 2020-09-30 | 12,196 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 251,935 | USD | 91 |
| 2021-10-01 to 2022-06-30 | -765,082 | USD | 273 |
| 2022-01-01 to 2022-03-31 | -1,035,741 | USD | 90 |
| 2021-10-01 to 2021-12-31 | 18,724 | USD | 92 |
| 2021-04-01 to 2021-06-30 | -142,228 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -3,700,772 | USD | 273 |
| 2021-01-01 to 2021-03-31 | -3,141,434 | USD | 90 |
| 2020-10-01 to 2020-12-31 | -417,110 | USD | 92 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | -334,309 | USD | 273 |
| 2020-10-01 to 2021-06-30 | -151,237 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 313,708 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 220,381 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -12,464,499 | USD | |
| At 2021-09-30 | -11,699,417 | USD |
Basic weighted-average shares
Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 406,566,324 | shares | 91 |
| 2021-10-01 to 2022-06-30 | 395,041,232 | shares | 273 |
| 2021-04-01 to 2021-06-30 | 351,763,390 | shares | 91 |
| 2020-10-01 to 2021-06-30 | 271,420,624 | shares | 273 |
Diluted weighted-average shares
Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 613,471,911 | shares | 91 |
| 2021-10-01 to 2022-06-30 | 395,041,232 | shares | 273 |
| 2021-04-01 to 2021-06-30 | 351,763,390 | shares | 91 |
| 2020-10-01 to 2021-06-30 | 271,420,624 | shares | 273 |
Basic earnings per share
Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 0 | USD/shares | 91 |
| 2021-10-01 to 2022-06-30 | 0 | USD/shares | 273 |
| 2021-04-01 to 2021-06-30 | 0 | USD/shares | 91 |
| 2020-10-01 to 2021-06-30 | -0.01 | USD/shares | 273 |
Diluted earnings per share
Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 0 | USD/shares | 91 |
| 2021-10-01 to 2022-06-30 | 0 | USD/shares | 273 |
| 2021-04-01 to 2021-06-30 | 0 | USD/shares | 91 |
| 2020-10-01 to 2021-06-30 | -0.01 | USD/shares | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | -241,218 | USD | 91 |
| 2021-10-01 to 2022-06-30 | -903,738 | USD | 273 |
| 2021-04-01 to 2021-06-30 | -232,380 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -470,953 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 1,990,691 | USD | |
| At 2021-09-30 | 2,026,415 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 621,933 | USD | |
| At 2021-09-30 | 579,851 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 316 | USD | |
| At 2021-09-30 | 290 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 241,218 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 903,738 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 232,380 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 470,953 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 424,421,269 | shares | |
| At 2021-09-30 | 381,171,269 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 10,117,722 | USD | |
| At 2021-09-30 | 9,680,572 | USD |
Accumulated other comprehensive income or loss
Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 12,574 | USD | |
| At 2021-09-30 | -8,378 | USD |
Total equity including noncontrolling interests
Equity including the portion attributable to noncontrolling interests. It is larger than or equal to parent stockholders equity and is not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | -1,937,738 | USD | |
| At 2022-03-31 | -2,402,450 | USD | |
| At 2021-12-31 | -1,584,439 | USD | |
| At 2021-09-30 | -1,692,700 | USD | |
| At 2021-06-30 | -1,841,178 | USD | |
| At 2021-03-31 | -1,870,668 | USD | |
| At 2020-12-31 | -1,753,252 | USD | |
| At 2020-09-30 | -2,934,105 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2022-06-30 | 166,592 | USD | |
| At 2021-09-30 | 347,491 | USD |
Comprehensive income or loss
Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 292,820 | USD | 91 |
| 2021-10-01 to 2022-06-30 | -744,130 | USD | 273 |
| 2021-04-01 to 2021-06-30 | -155,360 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -3,769,058 | USD | 273 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 16,345 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 64,462 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 20,716 | USD | 91 |
| 2020-10-01 to 2021-06-30 | 64,376 | USD | 273 |
Other nonoperating income or expense
Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2022-04-01 to 2022-06-30 | 493,153 | USD | 91 |
| 2021-10-01 to 2022-06-30 | 138,656 | USD | 273 |
| 2021-04-01 to 2021-06-30 | 90,152 | USD | 91 |
| 2020-10-01 to 2021-06-30 | -3,229,819 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 0 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 0 | USD | 273 |
Income taxes paid, net
Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 0 | USD | 273 |
| 2020-10-01 to 2021-06-30 | 0 | USD | 273 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-10-01 to 2022-06-30 | 26 | USD | 273 |
| 2020-10-01 to 2021-06-30 | -207 | USD | 273 |
Inspect the source
- Entity
- PHARMAGREEN BIOTECH INC. / CIK 0001435181
- Captured
- SEC response SHA-256
4e00c9aee679589f8868ed439479e9b4ea1a271d889b232e7bdda4b499a910e3
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001435181.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))